Richard I Steinhart is Chief Financial Officer of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 6,441 shares of BTAI, which is worth approximately $43,798. The most recent transaction as insider was on Mar 15, 2023, when has been sold 2,084 shares (Common Stock) at a price of $19.5 per share, resulting in proceeds of $40,638. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6.44K
369.12% 3M change
17.62% 12M change
Total Value Held $43,798

Richard I Steinhart Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 15 2023
SELL
Open market or private sale
$40,638 $19.5 p/Share
2,084 Reduced 58.15%
1,500 Common Stock
Mar 14 2023
BUY
Exercise of conversion of derivative security
-
2,084 Added 36.77%
3,584 Common Stock
Feb 01 2021
SELL
Open market or private sale
$180,563 $48.15 p/Share
3,750 Reduced 71.43%
1,500 Common Stock
Feb 01 2021
BUY
Exercise of conversion of derivative security
$20,813 $5.55 p/Share
3,750 Added 41.67%
5,250 Common Stock

Also insider at

ATOS
ATOSSA THERAPEUTICS, INC. Healthcare
ATNM
Actinium Pharmaceuticals, Inc. Healthcare
RIS

Richard I Steinhart

Chief Financial Officer
New Haven, CT

Track Institutional and Insider Activities on BTAI

Follow BioXcel Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTAI shares.

Notify only if

Insider Trading

Get notified when an Bio Xcel Therapeutics, Inc. insider buys or sells BTAI shares.

Notify only if

News

Receive news related to BioXcel Therapeutics, Inc.

Track Activities on BTAI